



**Date: 14<sup>th</sup> November, 2024**

**To,**  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400 051.

**Subject: Outcome of the Board Meeting of Nidan Laboratories and Healthcare Limited held on Thursday, 14<sup>th</sup> November, 2024.**

**Reference: NSE Symbol - NIDAN**

**Dear Madam/ Sir,**

This is to inform you that pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, the Board of Directors of the Company at its meeting held today have:

1. Approved the unaudited Financial Results of the Company for the half year ended 30<sup>th</sup> September, 2024;
2. Taken on record the Limited review Report by the Statutory Auditors of the Company for the aforesaid results;

In view of the above, we hereby enclose the following:

1. Unaudited Financial Results of the Company for the half year ended 30<sup>th</sup> September, 2024.
2. Limited Review Report on unaudited Financial Results of the Company for the half year ended 30<sup>th</sup> September, 2024.

The meeting of the Board of Directors of the Company commenced at 1.30 PM and concluded at 2.30 PM

This is for your information and records.

For **Nidan Laboratories and Healthcare Limited**

**Tejal Anil Jayakar**

**Director & CFO**

**DIN: 07984686**





**Date: 14<sup>th</sup> November, 2024**

**To,**  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400 051.

**Subject: Certificate of Non-Applicability of Reg 23(9) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended September 30,2024.**

**Reference: NSE Symbol - NIDAN**

**Dear Madam / Sir,**

As per Regulation 15 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the compliance with the corporate governance provisions as specified in Regulation 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and para C, D and E of Schedule V shall not apply, in respect of -

- The listed entity having paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty-five crore, as on the last day of previous financial year.
- The listed entity which has listed its specified securities on the SME Exchange.

Our Company is a SME listed and as we fall under the aforesaid exemption, a compliance with the disclosure of Related Party transactions provision specified in the aforesaid Regulation shall not be applicable to the Company.

Kindly take the above on record.

**For Nidan Laboratories and Healthcare Limited**

**Tejal Anil Jayakar**  
**Director & CFO**  
**DIN: 07984686**




**Nidan Laboratories And Healthcare Limited**  
CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303  
Tel No. +91 8975610000, E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in  
Statement of Unaudited Financial Results for the half year Ended as on 30th September 2024.

|          | Particulars  | Half Year ended (Rs in lakhs) |                 |                 | Year Ended      |
|----------|--|-------------------------------|-----------------|-----------------|-----------------|
|          |  | 30-Sep-24                     | 30-Sep-23       | 31-Mar-24       | 31-Mar-24       |
|          |  | UnAudited                     | Unaudited       | Audited         | Audited         |
| <b>1</b> | <b>Income</b>  |                               |                 |                 |                 |
|          | a) Revenue from Operations   | 1,053.27                      | 1,182.44        | 1,235.30        | <b>2,417.74</b> |
|          | b) Other Income  | 103.09                        | 152.30          | 122.34          | 274.64          |
|          | <b>Total Income (a+b)</b>  | <b>1,156.36</b>               | <b>1,334.74</b> | <b>1,357.64</b> | <b>2,692.38</b> |
| <b>2</b> | <b>Expenses</b>  |                               |                 |                 |                 |
|          | a) Cost of Materials Consumed  | 47.99                         | 47.40           | 47.60           | 95.00           |
|          | b) Changes in inventories of Finished Goods, Work in Progress and Stock- in- Trade | (0.79)                        | 16.15           | (9.82)          | 6.33            |
|          | c) Employee benefit expenses   | 183.82                        | 227.95          | 232.33          | 460.28          |
|          | d) Finance Costs   | 87.93                         | 97.69           | 120.37          | 218.06          |
|          | e) Depreciation and Amortization expenses  | 133.55                        | 127.52          | 159.08          | 286.60          |
|          | f) Other Expenses  | 562.48                        | 557.85          | 653.86          | 1,211.72        |
|          | <b>Total Expenses (a to f)</b>   | <b>1,014.99</b>               | <b>1,074.56</b> | <b>1,203.41</b> | <b>2,277.98</b> |
| <b>3</b> | <b>Profit before Exceptional and Extraordinary Items &amp; Tax</b>                 | <b>141.37</b>                 | <b>260.18</b>   | <b>154.23</b>   | <b>414.40</b>   |
| <b>4</b> | <b>Exceptional &amp; Extraordinary Items</b>                                       | -                             | -               | <b>651.27</b>   | 651.27          |
| <b>5</b> | <b>Profit before Tax and after exceptional &amp; extraordinary item (3-4)</b>      | <b>141.37</b>                 | <b>260.18</b>   | <b>(497.04)</b> | <b>(236.87)</b> |
| <b>6</b> | <b>Tax Expenses</b>  |                               |                 |                 |                 |
|          | a) Current Tax   | 36.00                         | 67.98           | 52.02           | 120.00          |
|          | b) Deferred Tax Asset/ Liability   | (4.75)                        | 1.86            | (35.51)         | (33.65)         |
|          | c) Tax of earlier year   | -                             | (1.90)          | 1.91            | 0.01            |
|          | <b>Total tax expenses</b>  | <b>31.25</b>                  | <b>67.94</b>    | <b>18.43</b>    | <b>86.37</b>    |
| <b>7</b> | <b>Profit for the period / year</b>  | <b>110.13</b>                 | <b>192.24</b>   | <b>(515.47)</b> | <b>(323.24)</b> |
| <b>8</b> | Paid-up equity share capital<br>(Face value of Rs 10/- per share )                 | 1,390                         | 1,390           | 1,390           | 1,390           |
|          | <b>Earnings Per Share (not annualized)</b>   |                               |                 |                 |                 |
|          | a) Basic EPS   | 0.79                          | 1.38            | -3.71           | -2.33           |
| <b>9</b> | b) Diluted EPS   | 0.79                          | 1.38            | (3.71)          | (2.33)          |

**Notes:**

- 1) The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 14th November 2024.
- 2) The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsory adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February, 2015 issued by ministry of corporate affairs.
- 3) During the year the Company has done investment in one of the group company of Rs 2000 lakhs
- 4) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.
- 5) The figures of the corresponding previous half year have been regrouped/rearranged wherever considered necessary to make them comparable



For and on behalf of Board of Directors  
Nidan Laboratories and Healthcare Limited

*(Signature)*  
Tejal Anil Jayakar  
Director & CFO  
DIN:07984686


Date : 14th November 2024  
Place : Virar



**Nidan Laboratories And Healthcare Limited**  
**Statement of Assets & Liabilities as at 30th September 2024**

Rs in lakhs

|           | Particulars   | As at<br>30th September 2024<br>(UnAudited) | As at<br>31st March 2024<br>(Audited) |
|-----------|---|---|---------------------------------------|
| <b>I</b>  | <b>Equity &amp; Liabilities</b>                           |   |                                       |
|           | <b>1. Shareholders' funds</b>                             |   |                                       |
|           | Equity Share Capital                                      | 1,390.00                                    | 1,390.00                              |
|           | Reserves and Surplus                                      | 5,340.73                                    | 5,230.61                              |
|           |   | <b>6,730.73</b>                             | <b>6,620.61</b>                       |
|           | <b>2. Non - Current Liabilities</b>                       |   |                                       |
|           | (a) Long - Term Borrowings                                | 426.62                                      | 429.38                                |
|           | (b) Other Long term liabilities                           | 17.29                                       | 16.64                                 |
|           | (c) Long Term Provisions                                  | 56.47                                       | 56.47                                 |
|           |   | <b>500.38</b>                               | <b>502.50</b>                         |
|           | <b>3. Current Liabilities</b>                             |   |                                       |
|           | (a) Short - Term Borrowings                               | 749.89                                      | 814.08                                |
|           | (b) Trade Payables  |   |                                       |
|           | (i) Total outstanding due of micro enterprises and small  | 13.16                                       | 15.42                                 |
|           | (ii) Total outstanding dues of creditors other than micro |   |                                       |
|           | enterprises and small enterprises                         | 81.66                                       | 57.54                                 |
|           | (c) Other Current Liabilities                             | 116.42                                      | 127.30                                |
|           | (d) Short - Term Provisions                               | 152.91                                      | 117.62                                |
|           |   | <b>1,114.04</b>                             | <b>1,131.97</b>                       |
|           | <b>TOTAL</b>  | <b>8,345.15</b>                             | <b>8,255.08</b>                       |
| <b>II</b> | <b>Assets</b>   |   |                                       |
|           | <b>1. Non - Current Assets</b>                            |   |                                       |
|           | (a) Property Plant & Equipment and Intangible Assets      |   |                                       |
|           | (i) Property, Plant & Equipments                          | 1,741.64                                    | 1,793.51                              |
|           | (ii) Intangible Asset                                     | 1.51  | 1.71                                  |
|           | (iii) Capital workin progress                             | 6.33  | 3.50                                  |
|           | (b) Non-Current Investments                               | 2,000.00                                    | -                                     |
|           | (c) Long - Term Loans and Advances                        | 3,355.46                                    | 3,276.82                              |
|           | (d) Deferred Tax Asset (Net)                              | 86.71                                       | 81.95                                 |
|           | (e) Other Non Current Assets                              | 70.72                                       | 69.82                                 |
|           |   | <b>7,262.37</b>                             | <b>5,227.30</b>                       |
|           | <b>2. Current Assets</b>                                  |   |                                       |
|           | (a) Inventories   | 30.99                                       | 30.19                                 |
|           | (b) Trade Receivables                                     | 50.16                                       | 52.44                                 |
|           | (c) Cash and Cash Equivalents                             | 279.54                                      | 284.99                                |
|           | (d) Short - Term Loans and Advances                       | 335.71                                      | 2,396.25                              |
|           | (e) Other Current Assets                                  | 386.38                                      | 263.91                                |
|           |   | <b>1,082.78</b>                             | <b>3,027.78</b>                       |
|           | <b>TOTAL</b>  | <b>8,345.15</b>                             | <b>8,255.08</b>                       |



For and on behalf of Board of Directors  
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar  
Director & CFO  
DIN:07984686

Date : 14th November 2024  
Place : Virar




**Nidan Laboratories And Healthcare Limited**  
**Statement Of Cash Flows For The half year ended 30th September 2024**

| Particulars   | Rs. in lakhs                           |                               |
|---|--|-------------------------------|
|   | Half Year ended<br>30th September 2024 | Year ended<br>31st March 2024 |
| <b>A - CASH FLOW FROM OPERATING ACTIVITIES</b>  |  |                               |
| Profit Before Tax   | 141.37                                 | (236.87)                      |
| <b>Add/ (less) Adjustment for:</b>  |  |                               |
| Interest Income   | (99.62)                                | (264.64)                      |
| Interest Expenses   | 85.90                                  | 199.17                        |
| Interest on income tax  | -                                      | 9.38                          |
| Sundry Balance w/off  | -                                      | 34.60                         |
| Depreciation on property plant & equipment  | 133.55                                 | 286.60                        |
| Loss on discard of Property plant & Equipment   | -                                      | 115.10                        |
| Provision for Doubtful debts  | -                                      | 536.17                        |
| (Gain)/loss on disposal of property, plant and equipment                                    | (3.16)                                 | 2.89                          |
| <b>Operating Profit Before Working Capital Changes</b>                                      | <b>258.04</b>                          | <b>682.40</b>                 |
| <b>Add/ (less): Adjustments for Changes in working capital:</b>                             |  |                               |
| (Increase) / decrease in Trade Receivable   | 2.28                                   | 14.00                         |
| (Increase) / decrease in Other Current Assets   | (122.47)                               | (11.51)                       |
| (Increase) / decrease in Other Non current assets   | (0.90)                                 | 2.49                          |
| (Increase) / decrease in Inventories  | (0.79)                                 | 6.33                          |
| Increase / (decrease) in Trade payables   | 21.86                                  | 52.36                         |
| Increase / (decrease) in Long term liability  | 0.65                                   | (0.10)                        |
| Increase / (decrease) in Other current Liability  | (10.89)                                | 73.51                         |
| Increase / (decrease) in Short Term Provision   | (0.68)                                 | 1.25                          |
| Increase / (decrease) in Long term Provisions   | -                                      | 11.24                         |
| <b>Cash Generated from Operations</b>   | <b>147.11</b>                          | <b>831.96</b>                 |
| Add/ (less) : Direct taxes paid (net of refund received)                                    | (0.05)                                 | (279.98)                      |
| <b>Net Cash Inflow / (outflow) from Operating Activities</b>                                | <b>147.06</b>                          | <b>551.98</b>                 |
| <b>B - CASH FLOW FROM INVESTING ACTIVITIES</b>  |  |                               |
| Acquisition of property, plant and equipment / intangible assets / Capital work in progress | (87.84)                                | (73.63)                       |
| Investment in group company   | (2,000.00)                             |                               |
| Proceeds from sale of property, plant and equipment   | 6.67                                   | 9.58                          |
| (Increase) / Decrease in Long term loans and advances (net)                                 | 20.98                                  | 1,032.41                      |
| (Increase) / decrease in Short Term Loans and Advances                                      | 2,060.54                               | (2,044.56)                    |
| Interest received   | -                                      | 15.96                         |
| <b>Net cash inflow/(outflow) from Investing Activities</b>                                  | <b>0.35</b>                            | <b>(1,060.24)</b>             |
| <b>C - CASH FLOW FROM FINANCING ACTIVITIES</b>  |  |                               |
| Proceeds / (repayment) of borrowings (net)  | (66.96)                                | 148.58                        |
| Interest Expenses   | (85.90)                                | (197.26)                      |
| <b>Net Cash inflow/(outflow) from Financing Activities</b>                                  | <b>(152.86)</b>                        | <b>(48.69)</b>                |
| <b>Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)</b>                       | <b>(5.45)</b>                          | <b>(556.95)</b>               |
| Add: Cash and Cash Equivalents at the beginning of the year                                 | 284.99                                 | 841.94                        |
| <b>Cash and Cash Equivalents at the end of the year</b>                                     | <b>279.54</b>                          | <b>284.99</b>                 |

Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows :

| Particulars                      | As at               |                 |
|----------------------------------|---------------------|-----------------|
|                                  | 30th September 2024 | 31st March 2024 |
| Cash on hand                     | 272.50              | 261.82          |
| Balances with Banks              | 7.04                | 23.17           |
| <b>Cash and Cash Equivalents</b> | <b>279.54</b>       | <b>284.99</b>   |



For and on behalf of the Board of Directors  
Nidan Laboratories And Healthcare Limited

*(Signature)*  
Tejal Anil Jayakar  
Director & CFO  
DIN: 07984686

Date : 14th November 2024  
Place : Virar



**Nidan Laboratories And Healthcare Limited**

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,  
Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Statement of Unaudited Financial Results for the half year Ended on 30th September 2024

| S.No | Particulars  | Half Year Ended<br>30th September<br>2024<br>(UnAudited) | Half Year Ended<br>30th September<br>2023<br>(Unaudited) | Half Year<br>Ended 31st<br>March 2024<br>(Audited ) | Year Ended<br>31st March<br>2024<br>(Audited ) |
|------|--|--|--|---|--|
| 1    | Total Income from Operations   | 1,053.27   | 1,182.44   | 1,235.30  | 2,417.74                                       |
| 2    | Net Profit for the period / year (before tax, exceptional and/or extraordinary items)  | 141.37   | 260.18   | 154.23  | 414.40   |
| 3    | Net Profit for the period / year before tax (after exceptional and/or extraordinary items)   | 141.37   | 260.18   | (497.04)  | (236.87)                                       |
| 4    | Net Profit for the period / year after tax (after exceptional and/or extraordinary items)  | 110.13   | 192.24   | (515.47)  | (323.24)                                       |
| 5    | Total Comprehensive income for the period /year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)] | 110.13   | 192.24   | (515.47)  | (323.24)                                       |
| 6    | Paid up Equity Share Capital   | 1,390.00   | 1,390.00   | 1,390.00  | 1,390.00                                       |
| 7    | Reserves (exluding revaluation reserve)  | 5,340.73   | 5,746.09   | (515.48)  | 5,230.61                                       |
| 8    | Earnings Per Share (of Rs 10/-each) (not annualized)   |  |  |   |  |
|      | Basic  | 0.79   | 1.38   | -3.71   | -2.33  |
|      | Diluted  | 0.79   | 1.38   | -3.71   | -2.33  |

1) The above is an extract of the detailed format of Annual Financial Results filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period.



**For and on behalf of Board of Directors  
Nidan Laboratories and Healthcare Limited**

*Tejal Anil Jayakar*  
**Tejal Anil Jayakar  
Director & CFO  
DIN:07984686**

Date : 14th November 2024

Place : Virar





# R. K. CHAPAWAT & CO.

## CHARTERED ACCOUNTANTS

**Office:** 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West), Dist- Palghar : 401303.  
**Contact :** 9766095540 / 9769132203, **E-mail :** ravindra\_chapawat@rediffmail.com / info.chapawat@gmail.com

**Limited Review Report on unaudited financial results of Nidan Laboratories & Healthcare Limited for the half year ended 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of Nidan Laboratories & Healthcare Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of **Nidan Laboratories & Healthcare Limited** ("the Company") for the Half Year ended 30<sup>th</sup> September 2024 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.K Chapawat & Co.  
Chartered Accountants  
Firm's Registration No. 101708W

*Kamlesh Chapawat*

Kamlesh Chapawat  
Partner

M. No. 181441

UDIN: - 24181441BKGENA5729

Place: Virar

Date: 14<sup>th</sup> November 2024

